Elucidating the mechanisms by which IL-17-mediates p53 modulation is central not only in the context of intracellular infections, but also considering the fact that several studies involving the axis IL-17/p53 in cancer have been undertaken (27, 28, 32) and that IL-17-based therapies are being developed (33). This evidence concerns the gene IL17A and cancer.